Pancreatic Cell News 9.39 October 2, 2018 | |
| |
TOP STORYRadiation-induced decreases in clonogenic survival and double-stranded DNA breaks in tumor cells, but not in normal cells, were enhanced by pharmacological ascorbate (P-AscH-), while radiation-induced intestinal damage, collagen deposition, and oxidative stress were also reduced with P-AscH- in normal tissue. [Cancer Res] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISExendin-4 increased the expression and secretion of fibroblast growth factor (FGF)21 in αTC1-9 cells and β-cell-ablated islets. FGF21 treatment of β-cell-ablated islets increased the expression of PDX-1 and neurogenin-3 and significantly increased insulin+glucagon+ cells. [Diabetes] Abstract Researchers showed that inhibition of B cell lymphoma 2 (Bcl-2) via ABT-199 neither elicited intracellular Ca2+ signaling on its own nor potentiated Ca2+ signaling induced by physiological/pathophysiological stimuli in pancreatic acinar cells. [Br J Pharmacol] Abstract The authors studied the effect of cortistatin on pancreatic beta-cells and glucose-stimulated insulin secretion (GSIS). Exposure of isolated mouse islets to cortistatin inhibited GSIS. This effect was prevented using a somatostatin receptor antagonist. Cortistatin hyperpolarized the membrane potential and reduced glucose-induced action potentials in isolated pancreatic beta-cells. [Mol Cell Endocrinol] Abstract | Graphical Abstract Spexin in the Physiology of Pancreatic Islets-Mutual Interactions with Insulin Scientists found the presence of spexin inside beta cells and an increase in its release from islets after a short term and decrease after a long term following glucose administration. Negative feedback loops between spexin and insulin were found, indicating the presence of multilateral relationships between glucose, insulin, and spexin inside pancreatic islets. [Endocrine] Abstract PANCREATIC CANCERAn in vitro proliferation synergy screen was conducted to evaluate the response of a panel of high passage and patient-derived pancreatic cancer models to the combination of trametinib and palbociclib to inhibit MEK and CDK4/6, respectively. Two adenosquamous carcinoma models, L3.6pl and UM59, stood out for their high synergy response. [Mol Cancer Ther] Abstract | Full Article Investigators revealed that MEG8 associated with enhancer of zeste 2 polycomb repressive complex 2 subunit protein and induced its recruitment to the regulatory regions of the two microRNA genes for histone H3 methylation and transcriptional repression. [J Biol Chem] Abstract | Full Article Scientists demonstrated that combining the dual PI3K/mTOR inhibitor PF5212384 and MEK inhibitor PD325901 more effectively induced apoptosis compared with either agent alone, independent of KRAS mutational status in pancreatic ductal adenocarcinoma cell lines. [Cancer Biol Ther] Full Article Itraconazole Inhibits Proliferation of Pancreatic Cancer Cells through Activation of Bak-1 Researchers showed that itraconazole inhibited the growth of pancreatic cancer cells in vitro, and it also significantly inhibited the tumor growth of CFPAC-1 xenografts in vivo. Itraconazole induced apoptosis through ROS generation and mitochondrial membrane depolarization. A Bak-1 activation dependent apoptosis was identified in CFPAC-1 cells. [J Cell Biochem] Abstract Rab14 siRNA knockdown inhibited proliferation and colony formation ability in the Capan-2 cell line. Investigators showed that Rab14 facilitated cell cycle progression. They showed that Rab14 promoted BxPC-3 cell invasion while its depletion inhibited Capan-2 cell invasion. [Virchows Arch] Abstract Subscribe to one of our other 19 science newsletters such as Hepatic Cell News & Intestinal Cell News. | |
| |
REVIEWSThe Potential of CAR T Cell Therapy in Pancreatic Cancer The authors summarize the available preclinical data and highlight early phase clinical trials using chimeric antigen receptor (CAR) T cell approaches in pancreatic cancer, a disease state that is gaining attention as a conduit for cell therapy. [Front Immunol] Full Article Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
SCIENCE NEWSOrgenesis Announces Poster Presentation Orgenesis Inc. announced that Professor Sarah Ferber, Ph.D., Founder and Chief Scientific Officer of Orgenesis, will present a poster. The poster is entitled “The Epigenetic Characteristics of Liver to Pancreas Transdifferentiation,”. [Press release from Orgenesis Inc. discussing research to be presented at the 54th Annual Meeting of the European Association of the Study of Diabetes (EASD), Berlin] Press Release Valeritas Holdings, Inc. presented positive clinical and economic outcomes for V-Go compared to standard multiple daily injections insulin therapy for treating people with type 2 diabetes. [Press release from Valeritas, Inc discussing research presented at the 54th Annual Meeting of the European Association of the Study of Diabetes (EASD), Berlin] Press Release | |
| |
INDUSTRY NEWSReadouts from two Phase III clinical trials demonstrated that Eli Lilly and Company’s URLi met the primary efficacy endpoint of non-inferior A1C reduction from baseline compared to Humalog® and also demonstrated significantly improved post-meal glucose control in people with type 1 and type 2 diabetes. [Eli Lilly and Company] Press Release Zealand Pharma A/S announced initiation of the Phase III trial with dasiglucagon for treatment of severe hypoglycemia in children. This Phase III trial focuses on treating children with type 1 diabetes with a single dose of dasiglucagon to rapidly increase blood glucose levels following insulin-induced hypoglycemia. [Zealand Pharma A/S] Press Release GeNeuro Announces Positive 6-Month Phase IIa Data for GNbAC1 in Adults with Type 1 Diabetes GeNeuro announced that its Phase IIa study of GNbAC1 in type 1 diabetes (T1D) met the primary endpoint of safety in this new patient population. GNbAC1 is a monoclonal antibody designed to neutralize a pathogenic envelope protein, pHERV-W Env, which has been detected post mortem in about two thirds of the pancreas of patients with T1D. [GeNeuro SA] Press Release PharmaCyte Biotech Reports Completion of Crucial FDA-Required Study for Pancreatic Cancer Trial PharmaCyte Biotech, Inc. announced that it has successfully determined the modified site and chromosome location of the cytochrome P450-2B1 gene in the DNA of the genetically altered human cells known as 22P1G that will be encapsulated and used together with the cancer prodrug ifosfamide in PharmaCyte’s upcoming clinical trial. [PharmaCyte Biotech Inc.] Press Release $1.6 Million CIRM Grant Supports Potential Diabetes Treatment There are two main challenges to transplanting insulin-producing islet cells: the shortage of transplantable cells and the underlying autoimmune response that destroyed the patient’s own islets. Ronald Evans, a professor in Salk’s Gene Expression Laboratory and a Howard Hughes Medical Institute Investigator, believes that the development of immune tolerant human islet-like organoids, or HILOs for short, may be a solution. The California Institute for Regenerative Medicine (CIRM) recently approved a $1.6 million grant to help bring Evans’ HILOs to patients with diabetes. [Salk Institute for Biological Studies] Press Release The University of Birmingham has been awarded £1.78 million by the Wellcome Trust for research aimed at finding new therapies to treat diseases such as heart failure, diabetes and neurodegenerative disorders. [University of Birmingham] Press Release | |
| |
POLICY NEWSU.K. Scientists ‘Are Going to Be All Right,’ After Brexit, Science Minister Promises In January, U.K. Prime Minister Theresa May appointed Sam Gyimah as science and universities minister as a part of a broader cabinet reshuffle. During his visit, Gyimah spoke with Science about the United Kingdom’s withdrawal from the European Union, a topic that is causing a great deal of anxiety among U.K. scientists. [ScienceInsider] Editorial China To Train African Scientists as Part of $60-Billion Development Plan China wants to train Africa’s next generation of scientists. Its lofty goal is to improve African science in fields from agriculture and climate change to quantum physics and artificial intelligence. [Nature News] Editorial Airlines Fight Effort to Force Them to Carry Lab Animals A last-ditch attempt by biomedical science advocates to force airlines to transport nonhuman primates and other research animals appears to be facing stiff headwinds. Last week, four international carriers strongly urged the U.S. Department of Transportation (DOT) to summarily reject a plea from a leading research advocacy organization to order the airlines to resume flying animals to research facilities around the world. [ScienceInsider] Editorial
| |
EVENTSNEW Nature Conference on Cellular Metabolism Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Islet Biology (University of Alberta) Research Technologist – Pancreatic (STEMCELL Technologies Inc.) Postdoctoral Researcher – Identifying Cell Surface Receptor (Ionis Pharmaceuticals, Inc.) Postdoctoral Position – Metabolic Inflammation in Diabetes (Inserm) Assistant Professor – Biomedical Sciences (New York Institute of Technology) Scientists – Diabetes Research (Qatar Biomedical Research Institute) Caspar Wistar Fellows – Cancer Biology (The Wistar Institute) Postdoctoral Researcher – Diabetes Research (UC San Diego School of Medicine) Postdoctoral Positions – Immunology of Diabetes (Cochin Institute) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|